Lanean...
The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer
Activating RAS mutations are common in human tumors. These mutations are often markers for resistance to therapy and subsequent poor prognosis. So far, targeting the RAF-MEK-ERK and PI3K-AKT signaling pathways downstream of RAS is the only promising approach in the treatment of cancer patients harbo...
Gorde:
| Argitaratua izan da: | Acta Pharmacol Sin |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4349922/ https://ncbi.nlm.nih.gov/pubmed/25557115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2014.129 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|